An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Recruiting now · Phase 3

Conditions studied: Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis

In brief

The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.

Key facts

Study ID

NCT06668181

Run by

UCB Biopharma SRL

People needed

40

Starts

2025-03-11

Expected to finish

2030-07-31

Last updated by the study team

2026-07-17

Who can join

Age: 2 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Study participant must be 2 to <18 years of age inclusive, at the Baseline Visit.
• Study participants who have confirmed diagnosis of enthesitis-related arthritis (ERA; including juvenile-onset ankylosing spondylitis (JAS)) and/or juvenile psoriatic arthritis (JPsA) according to the juvenile-International League of Associations for Rheumatology (JIA-ILAR) classification criteria of at least 3 months duration prior to the Screening Visit.
• Study participants who have active disease (ERA [including JAS] and/or JPsA) defined as having at least 3 active joints, each of which needs to be included in the joints assessed in the JADAS27, and for ERA at least 1 site of enthesitis at Baseline or documented by history.
• Study participants with inadequate response (at least 1 month) or intolerance to at least 1 nonsteroidal anti-inflammatory drug (NSAID).
• Study participants taking concomitant methotrexate or sulfasalazine are allowed to continue the medication if it has been used for the past 12 weeks with a stable dose for the 4 weeks prior to Baseline, with no change in dose for the first 16 weeks of treatment foreseen. (Note: prior or concomitant use of methotrexate or sulfasalazine is NOT required for study participation.)
• Study participants with no concomitant use of second line agents such as disease-modifying and/or immunosuppressive drugs with the exception of methotrexate or sulfasalazine.
• Body weight of ≥10kg.
• Male and female.
• A female study participant will be eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:
• Not a woman of childbearing potential (WOCBP) OR
• A WOCBP who agrees to follow the contraceptive guidance during the Initial Treatment Period, the Open-label Extension (OLE) Period, and for at least 20 weeks after the final dose of investigational medicinal product (IMP; ie, the Safety Follow-up (SFU) Period)
• Capable of giving/having parent(s) or legal representative provide signed informed consent/assent (where appropriate), which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and assent and in this protocol.

You may not qualify if…

• Study participants fulfilling any International League of Associations for Rheumatology (ILAR) diagnostic juvenile idiopathic arthritis (JIA) category other than enthesitis-related arthritis (ERA; including juvenile-onset ankylosing spondylitis (JAS)) and/or juvenile psoriatic arthritis (JPsA).
• Study participant has history of inflammatory bowel disease (IBD) or signs/symptoms suggestive of IBD.
• Study participant has active uncontrolled uveitis.
• Study participant has history of active tuberculosis (TB) unless successfully treated, latent TB unless prophylactically treated.
• Study participant has had major surgery (including joint surgery) within the 3 months prior to the Baseline Visit or has planned major surgery within 6 months after entering the study.
• Study participant has laboratory abnormalities at Screening defined in the Protocol.
• Study participant has an active infection or history of infections (such as serious infection, chronic infections, opportunistic infections, unusually severe infections).
• Study participant has received drugs listed in the protocol outside the specified timeframes relative to the Baseline Visit or receives prohibited concomitant treatments.
• Study participant had previous therapy with bimekizumab or prior treatment with other IL-17 biologic response modifier.
• Study participant had prior treatment with more than one biologic response modifier (other than an IL-17).
• Presence of active suicidal ideation, or positive suicide behavior.
• Study participant has been diagnosed with severe depression in the past 6 months.

Where it is running

• Ja0005 50646 — Calgary, Canada (enrolling)
• Ja0005 50644 — Montreal, Canada (enrolling)
• Ja0005 50645 — Saskatoon, Canada (enrolling)
• Ja0005 40777 — Indre-et-Loire, France (enrolling)
• Ja0005 40510 — Le Kremlin-Bicêtre, France (enrolling)
• Ja0005 40778 — Paris, France (enrolling)
• Ja0005 40776 — Poitiers, France (enrolling)
• Ja0005 40369 — Berlin, Germany (enrolling)
• Ja0005 40356 — Dresden, Germany (enrolling)
• Ja0005 40072 — Freiburg im Breisgau, Germany (enrolling)
• Ja0005 40852 — Hamburg, Germany (enrolling)
• Ja0005 40787 — Sankt Augustin, Germany (enrolling)
• Ja0005 40779 — Sendenhorst, Germany (enrolling)
• Ja0005 40427 — Tübingen, Germany (enrolling)
• Ja0005 40720 — Krakow, Poland (enrolling)
• Ja0005 40780 — Sosnowiec, Poland (enrolling)
• Ja0005 40781 — Esplugues de Llobregat, Spain (enrolling)
• Ja0005 40100 — Madrid, Spain (enrolling)
• Ja0005 40782 — Valencia, Spain (enrolling)
• Ja0005 40786 — Bristol, United Kingdom (enrolling)
• Ja0005 40783 — Manchester, United Kingdom (enrolling)
• Ja0005 40785 — Nottingham, United Kingdom (enrolling)
• Ja0005 40784 — Stroke-on-trent, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.